SCHEMBL7219796

SCHEMBL7219796

CC(C)(C)OC(=O)N1CCN(c2ccc(C3=NCCO3)cc2)CC1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.54
LMNA P02545 2/20 0.54
ALDH1A1 P00352 1/20 0.54
GPR119 Q8TDV5 8/20 0.52
SMN1; SMN2 Q16637 5/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
TSHR P16473 1/20 0.47
NAMPT P43490 1/20 0.47
JAK2 O60674 2/20 0.46
JAK3 P52333 2/20 0.46
CYP2C19 P33261 1/20 0.46
HTT P42858 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
RET P07949 1/20 0.45
USP2 O75604 1/20 0.45
PTK2 Q05397 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3486059 0.90 GPR119 (0.64) GPR119
SCHEMBL5573222 0.81 MAPT (0.76) MAPTLMNAALDH1A1GPR119SMN1; SMN2
SCHEMBL27025951 0.81 MAPT (0.58) MAPTLMNAALDH1A1GPR119SMN1; SMN2
SCHEMBL558083 0.80 GPR119 (0.54) GPR119HTT
SCHEMBL9138887 0.80 LSS (0.62) GPR119SMN1; SMN2USP2
SCHEMBL21876057 0.79 MAPT (0.62) MAPTLMNAALDH1A1GPR119SMN1; SMN2
SCHEMBL24990320 0.78 MAPT (0.61) MAPTLMNAALDH1A1GPR119SMN1; SMN2
SCHEMBL15006934 0.77 USP2 (0.50) MAPTLMNAALDH1A1GPR119SMN1; SMN2
SCHEMBL13279526 0.77 MAPT (0.64) MAPTLMNAALDH1A1GPR119SMN1; SMN2
SCHEMBL5542227 0.77 GPR119 (0.65) MAPTLMNAALDH1A1GPR119SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6589953-B2 Treatment of anxiety, depression, aggressiveness, panic attacks, obsessive-compulsive disorders, schizophrenia, suicidal tendency, neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease PIERRE FABRE MEDICAMENT (FR) 2003-07-08 US disclosed
US-20020061891-A1 Indole derivatives as 5-HT1B and 5-HT1D agonists PEREZ MICHEL (FR) 2002-05-23 US disclosed
US-6277853-B1 FOR TREATMENT OF NERVOUS SYSTEM DISORDERS, PSYCHOLOGICAL DISORDERS, MIGRAINES, ALCOHOLISM PIERRE FABRE MEDICAMENT (FR) 2001-08-21 US disclosed
CN-1272108-A Indole derivatives useful as 5-HT 1B and 5-HIT 1D agonists PF MEDICAMENT (FR) 2000-11-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020061891-A1 Indole derivatives as 5-HT1B and 5-HT1D agonists HTR1B, HTR1A, HTR1D MAPT 3195/4885LMNA 4076/4885ALDH1A1 358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.